Receptor-Targeted Nanoparticles for In vivo Imaging of Breast Cancer

Purpose: Cell-surface receptor-targeted magnetic iron oxide nanoparticles provide molecular magnetic resonance imaging contrast agents for improving specificity of the detection of human cancer. Experimental Design: The present study reports the development of a novel targeted iron oxide nanoparticle using a recombinant peptide containing the amino-terminal fragment of urokinase-type plasminogen activator (uPA) conjugated to magnetic iron oxide nanoparticles amino-terminal fragment conjugated-iron oxide (ATF-IO). This nanoparticle targets uPA receptor, which is overexpressed in breast cancer tissues. Results: ATF-IO nanoparticles are able to specifically bind to and be internalized by uPA receptor–expressing tumor cells. Systemic delivery of ATF-IO nanoparticles into mice bearing s.c. and i.p. mammary tumors leads to the accumulation of the particles in tumors, generating a strong magnetic resonance imaging contrast detectable by a clinical magnetic resonance imaging scanner at a field strength of 3 tesla. Target specificity of ATF-IO nanoparticles showed by in vivo magnetic resonance imaging is further confirmed by near-IR fluorescence imaging of the mammary tumors using near-IR dye-labeled amino-terminal fragment peptides conjugated to iron oxide nanoparticles. Furthermore, mice administered ATF-IO nanoparticles exhibit lower uptake of the particles in the liver and spleen compared with those receiving nontargeted iron oxide nanoparticles. Conclusions: Our results suggest that uPA receptor–targeted ATF-IO nanoparticles have potential as molecularly targeted, dual modality imaging agents for in vivo imaging of breast cancer.

[1]  D. Guyton,et al.  Urokinase Plasminogen Activator Receptor (uPAR): A Potential Indicator of Invasion for In Situ Breast Cancer , 2000, The breast journal.

[2]  Lily Yang,et al.  Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: implication for cancer specific therapy. , 2003, Cancer research.

[3]  M. Yaffe,et al.  American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography , 2007 .

[4]  P. Carmeliet,et al.  uPAR: a versatile signalling orchestrator , 2002, Nature Reviews Molecular Cell Biology.

[5]  J A Frank,et al.  Frequency dependence of MR relaxation times II. Iron oxides , 1993, Journal of magnetic resonance imaging : JMRI.

[6]  B. Deurs,et al.  Urokinase-type plasminogen activator receptor is internalized by different mechanisms in polarized and nonpolarized Madin-Darby canine kidney epithelial cells. , 1999, Molecular biology of the cell.

[7]  I. Giannopoulou,et al.  The prognostic value of the topographic distribution of uPAR expression in invasive breast carcinomas. , 2007, Cancer letters.

[8]  Ralph Weissleder,et al.  Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. , 2003, The New England journal of medicine.

[9]  Jinwoo Cheon,et al.  Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging , 2007, Nature Medicine.

[10]  R. Cheney,et al.  Accuracy of Pathologic Techniques for the Diagnosis of Metastatic Melanoma in Sentinel Lymph Nodes , 1999, Annals of Surgical Oncology.

[11]  S. Nie,et al.  Development of Receptor Targeted Magnetic Iron Oxide Nanoparticles for Efficient Drug Delivery and Tumor Imaging. , 2008, Journal of biomedical nanotechnology.

[12]  Anna Moore,et al.  In vivo imaging of siRNA delivery and silencing in tumors , 2007, Nature Medicine.

[13]  M. Hofmann.  From scinti-mammography and metabolic imaging to receptor targeted PET-new principles of breast cancer detection. , 2006, Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics.

[14]  Michael J Sailor,et al.  Biomimetic amplification of nanoparticle homing to tumors , 2007, Proceedings of the National Academy of Sciences.

[15]  V. Rajagopal,et al.  Recombinant Toxins That Bind to the Urokinase Receptor Are Cytotoxic without Requiring Binding to the α2-Macroglobulin Receptor* , 2000, The Journal of Biological Chemistry.

[16]  M. Ploug,et al.  Cell-surface acceleration of urokinase-catalyzed receptor cleavage. , 1997, European journal of biochemistry.

[17]  G. D'aiuto,et al.  Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels. , 1993, Cancer research.

[18]  P. Opolon,et al.  Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway. , 2005, Human gene therapy.

[19]  Anna Moore,et al.  In vivo imaging of tumor response to therapy using a dual‐modality imaging strategy , 2006, International journal of cancer.

[20]  François Bénard,et al.  Imaging in breast cancer: Single-photon computed tomography and positron-emission tomography , 2005, Breast Cancer Research.

[21]  S. Gambhir,et al.  Molecular imaging in living subjects: seeing fundamental biological processes in a new light. , 2003, Genes & development.

[22]  S. Nie,et al.  In vivo cancer targeting and imaging with semiconductor quantum dots , 2004, Nature Biotechnology.

[23]  Antony K. Chen,et al.  Superparamagnetic Iron Oxide Nanoparticle Probes for Molecular Imaging , 2006, Annals of Biomedical Engineering.

[24]  J. Kuhn,et al.  Hepatic Tumor Imaging Using Iron Oxide MRI: Comparison With Computed Tomography, Clinical Impact, and Cost Analysis , 1999, Annals of Surgical Oncology.

[25]  R. Weissleder.  Molecular Imaging in Cancer , 2006, Science.

[26]  M. Ploug,et al.  Structure—function relationships in the receptor for urokinase‐type plasminogen activator Comparison to other members of the Ly‐6 family and snake venom α‐neurotoxins , 1994 .

[27]  P. Quax,et al.  Binding of human urokinase-type plasminogen activator to its receptor: residues involved in species specificity and binding. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[28]  N. Brünner,et al.  Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. , 1994, Cancer research.

[29]  A. Söling,et al.  Bioluminescence imaging in vivo – application to cancer research , 2003, Expert opinion on biological therapy.

[30]  E. Dublin,et al.  Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology. , 2000, The American journal of pathology.

[31]  A. Harris,et al.  Expression of vascular endothelial growth factor by macrophages is up‐regulated in poorly vascularized areas of breast carcinomas , 2000, The Journal of pathology.

[32]  Rong Zhou,et al.  Iron oxide nanoparticles as magnetic resonance contrast agent for tumor imaging via folate receptor-targeted delivery. , 2004, Academic radiology.

[33]  B. Nielsen,et al.  Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor , 2007, International journal of cancer.

[34]  R. Hildenbrand,et al.  Urokinase plasminogen activator receptor (CD87) expression of tumor‐associated macrophages in ductal carcinoma in situ, breast cancer, and resident macrophages of normal breast tissue , 1999, Journal of leukocyte biology.

[35]  N. Brünner,et al.  Comparative evaluation of urokinase‐type plasminogen activator receptor expression in primary breast carcinomas and on metastatic tumor cells , 2003, International journal of cancer.

[36]  Wolfgang J Parak,et al.  Multifunctionalized polymer microcapsules: novel tools for biological and pharmacological applications. , 2007, Small.

[37]  Hua Ai,et al.  Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems. , 2006, Nano letters.

[38]  B. Han,et al.  Urokinase-type plasminogen activator system and breast cancer (Review). , 2005, Oncology reports.

[39]  Dmitri Artemov,et al.  Magnetic resonance molecular imaging of the HER-2/neu receptor. , 2003, Cancer research.

[40]  M. Ploug,et al.  Structure-function relationships in the receptor for urokinase-type plasminogen activator. Comparison to other members of the Ly-6 family and snake venom alpha-neurotoxins. , 1994, FEBS letters.

[41]  Jeff W M Bulte,et al.  Clinically applicable labeling of mammalian and stem cells by combining superparamagnetic iron oxides and transfection agents. , 2003, Radiology.

[42]  H. Friess,et al.  Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. , 1997, British Journal of Cancer.

[43]  M. Duffy,et al.  The urokinase plasminogen activator system: role in malignancy. , 2004, Current pharmaceutical design.

[44]  R Weissleder,et al.  Tumoral distribution of long-circulating dextran-coated iron oxide nanoparticles in a rodent model. , 2000, Radiology.

[45]  Jeff W M Bulte,et al.  Iron oxide MR contrast agents for molecular and cellular imaging , 2004, NMR in biomedicine.

[46]  J. Bruner,et al.  Expression and localization of urokinase-type plasminogen activator receptor in human gliomas. , 1994, Cancer research.

[47]  M. Duffy,et al.  Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer , 1995, International journal of cancer.

[48]  William W. Yu,et al.  Synthesis of monodisperse iron oxide nanocrystals by thermal decomposition of iron carboxylate salts. , 2004, Chemical communications.

[49]  P. Choong,et al.  Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases — A comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases , 2000, Breast Cancer Research and Treatment.